ISPOR - Anti-Tnf Biosimilars Indicated for Rheumatoid Arthritis are Increasingly Available in Europe- How Do Payers and Key Stakeholders Perceive Them?

Full Text

Anti-Tnf Biosimilars Indicated for Rheumatoid Arthritis are Increasingly Available in Europe- How Do Payers and Key Stakeholders Perceive Them?

Abstract

Authors

N.P.S. Sewak C. Jones

Back to Volume 17, Issue 7

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now